Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2


Ollier disease and Maffucci syndrome are characterized by multiple central cartilaginous tumors that are accompanied by soft tissue hemangiomas in Maffucci syndrome. We show that in 37 of 40 individuals with these syndromes, at least one tumor has a mutation in isocitrate dehydrogenase 1 (IDH1) or in IDH2, 65% of which result in a R132C substitution in the protein. In 18 of 19 individuals with more than one tumor analyzed, all tumors from a given individual shared the same IDH1 mutation affecting Arg132. In 2 of 12 subjects, a low level of mutated DNA was identified in non-neoplastic tissue. The levels of the metabolite 2HG were measured in a series of central cartilaginous and vascular tumors, including samples from syndromic and nonsyndromic subjects, and these levels correlated strongly with the presence of IDH1 mutations. The findings are compatible with a model in which IDH1 or IDH2 mutations represent early post-zygotic occurrences in individuals with these syndromes.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Clinical features of individuals with Ollier disease or Maffucci syndrome who harbor an IDH1 mutation encoding an R132C substitution.
Figure 2: Comparison of 2HG levels in tumors with wild-type (WT) or mutated IDH1 and IDH2.


  1. Unni, K.K. Cartilaginous lesions of bone. J. Orthop. Sci. 6, 457–472 (2001).

    CAS  Article  Google Scholar 

  2. Hopyan, S. et al. A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat. Genet. 30, 306–310 (2002).

    Article  Google Scholar 

  3. Pansuriya, T.C., Kroon, H.M. & Bovee, J.V. Enchondromatosis: insights on the different subtypes. Int. J. Clin. Exp. Pathol. 3, 557–569 (2010).

    PubMed  PubMed Central  Google Scholar 

  4. Dang, L., Jin, S. & Su, S.M. IDH mutations in glioma and acute myeloid leukemia. Trends Mol. Med. 16, 387–397 (2010).

    CAS  Article  Google Scholar 

  5. Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009).

    CAS  Article  Google Scholar 

  6. Figueroa, M.E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567 (2010).

    CAS  Article  Google Scholar 

  7. Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510–522 (2010).

    CAS  Article  Google Scholar 

  8. Amary, M.F. et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol. 224, 334–343 (2011).

    CAS  Article  Google Scholar 

  9. Pansuriya, T.C. et al. Genome-wide analysis of Ollier disease: is it all in the genes? Orphanet J. Rare Dis. 6, 2 (2011).

    Article  Google Scholar 

  10. Krell, D. et al. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PLoS ONE 6, e19868 (2011).

    CAS  Article  Google Scholar 

  11. Preusser, M. et al. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J. Neuropathol. Exp. Neurol. 70, 715–723 (2011).

    CAS  Article  Google Scholar 

Download references


We are grateful to the individuals who participated in the research and to the clinicians and support staff in the London Sarcoma Service involved in their care. The research was funded by Skeletal Cancer Action Trust (SCAT) UK, The Bone Cancer Research Trust UK and The Wellcome Trust (WT077012). This research was part of the Royal National Othopaedic Hospital Musculoskeletal Research Programme and Biobank and the University College London Hospital and University College London Comprehensive Biomedical Research Programme.

Author information

Authors and Affiliations



A.M.F., M.F.A. and A.F. conceived of the project. A.M.F., M.F.A., A.F., D.H. and N.P. planned the experiments. D.H., M.E., N.P., F. Berisha, S.L., C.L.G. and R.E.G. performed the experiments. F. Bonar, R.T., S.M., A.M.F., M.F.A. and W.A. reviewed the histopathology and selected and provided the samples. V.R.F. and K.S.S. performed 2HG measurements. A.M.F., M.F.A. and S.D. wrote the manuscript. P.C. performed the statistical analysis. All authors reviewed the manuscript.

Corresponding author

Correspondence to Adrienne M Flanagan.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Tables 1–4 (PDF 255 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Amary, M., Damato, S., Halai, D. et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 43, 1262–1265 (2011).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing